27920091|t|Interferon-γ Limits Diabetogenic CD8(+) T-Cell Effector Responses in Type 1 Diabetes
27920091|a|Type 1 diabetes development in the NOD mouse model is widely reported to be dependent on high - level production by autoreactive CD4(+) and CD8(+) T cells of interferon-γ (IFN-γ), generally considered a proinflammatory cytokine. However, IFN-γ can also participate in tolerance-induction pathways, indicating it is not solely proinflammatory. This study addresses how IFN-γ can suppress activation of diabetogenic CD8(+) T cells. CD8(+) T cells transgenically expressing the diabetogenic AI4 T-cell receptor adoptively transferred disease to otherwise unmanipulated NOD. IFN-γ (null), but not standard NOD, mice. AI4 T cells only underwent vigorous intrasplenic proliferation in NOD. IFN-γ (null) recipients. Disease -protective IFN-γ could be derived from any lymphocyte source and suppressed diabetogenic CD8(+) T-cell responses both directly and through an intermediary nonlymphoid cell population. Suppression was not dependent on regulatory T cells, but was associated with increased inhibitory STAT1 to STAT4 expression levels in pathogenic AI4 T cells. Importantly, IFN-γ exposure during activation reduced the cytotoxicity of human-origin type 1 diabetes - relevant autoreactive CD8(+) T cells. Collectively, these results indicate that rather than marking the most proinflammatory lymphocytes in diabetes development, IFN-γ production could represent an attempted limitation of pathogenic CD8(+) T-cell activation. Thus, great care should be taken when designing possible diabetic intervention approaches modulating IFN-γ production.
27920091	0	12	Interferon-γ	T103	UMLS:C3539881
27920091	20	55	Diabetogenic CD8(+) T-Cell Effector	T017	UMLS:C0242629
27920091	69	84	Type 1 Diabetes	T038	UMLS:C0011854
27920091	85	100	Type 1 diabetes	T038	UMLS:C0011854
27920091	120	135	NOD mouse model	T038	UMLS:C2986594
27920091	214	220	CD4(+)	T017	UMLS:C0039215
27920091	225	239	CD8(+) T cells	T017	UMLS:C0242629
27920091	243	255	interferon-γ	T103	UMLS:C3539881
27920091	257	262	IFN-γ	T103	UMLS:C3539881
27920091	304	312	cytokine	T103	UMLS:C0079189
27920091	323	328	IFN-γ	T103	UMLS:C3539881
27920091	353	372	tolerance-induction	T038	UMLS:C1817959
27920091	373	381	pathways	T038	UMLS:C1704259
27920091	453	458	IFN-γ	T103	UMLS:C3539881
27920091	472	482	activation	T038	UMLS:C1326120
27920091	486	513	diabetogenic CD8(+) T cells	T017	UMLS:C0242629
27920091	515	529	CD8(+) T cells	T017	UMLS:C0242629
27920091	530	555	transgenically expressing	T038	UMLS:C1171362
27920091	560	572	diabetogenic	T038	UMLS:C0011847
27920091	573	576	AI4	T038	UMLS:C1863012
27920091	577	592	T-cell receptor	T103	UMLS:C0034790
27920091	616	623	disease	T038	UMLS:C0012634
27920091	637	654	unmanipulated NOD	T204	UMLS:C0085243
27920091	656	661	IFN-γ	T103	UMLS:C3539881
27920091	687	696	NOD, mice	T204	UMLS:C0085243
27920091	698	701	AI4	T038	UMLS:C1863012
27920091	702	709	T cells	T017	UMLS:C0039194
27920091	747	760	proliferation	T038	UMLS:C0596290
27920091	764	767	NOD	T204	UMLS:C0085243
27920091	769	774	IFN-γ	T103	UMLS:C3539881
27920091	794	801	Disease	T038	UMLS:C0012634
27920091	814	819	IFN-γ	T103	UMLS:C3539881
27920091	846	856	lymphocyte	T017	UMLS:C0024264
27920091	879	905	diabetogenic CD8(+) T-cell	T017	UMLS:C0242629
27920091	906	915	responses	T038	UMLS:C0007613
27920091	958	969	nonlymphoid	T017	UMLS:C0040300
27920091	970	985	cell population	T017	UMLS:C0007634
27920091	1031	1038	T cells	T017	UMLS:C0039194
27920091	1085	1090	STAT1	T103	UMLS:C0287920
27920091	1094	1099	STAT4	T103	UMLS:C0255034
27920091	1100	1110	expression	T038	UMLS:C1171362
27920091	1132	1135	AI4	T038	UMLS:C1863012
27920091	1136	1143	T cells	T017	UMLS:C0039194
27920091	1158	1163	IFN-γ	T103	UMLS:C3539881
27920091	1180	1190	activation	T038	UMLS:C1326120
27920091	1203	1215	cytotoxicity	T038	UMLS:C0596402
27920091	1232	1247	type 1 diabetes	T038	UMLS:C0011854
27920091	1272	1286	CD8(+) T cells	T017	UMLS:C0242629
27920091	1375	1386	lymphocytes	T017	UMLS:C0024264
27920091	1390	1398	diabetes	T038	UMLS:C0011847
27920091	1412	1417	IFN-γ	T103	UMLS:C3539881
27920091	1483	1496	CD8(+) T-cell	T017	UMLS:C0242629
27920091	1497	1507	activation	T038	UMLS:C1326120
27920091	1521	1525	care	T058	UMLS:C0150544
27920091	1566	1574	diabetic	T038	UMLS:C0011847
27920091	1575	1587	intervention	T058	UMLS:C0184661
27920091	1588	1598	approaches	T082	UMLS:C0449445
27920091	1599	1609	modulating	T082	UMLS:C0443264
27920091	1610	1615	IFN-γ	T103	UMLS:C3539881